Potential and prospects of the astragaloside IV use for age-associated diseases prevention

Berezutsky M.A.; Matvienko U.A.; Durnova N.A.

doi:https://doi.org/10.17116/profmed20252807194

OBJECTIVE

To summarize and analyze the data of experimental studies on identification of pharmacological properties in astragaloside IV (main biologically active compound of astragalus membranaceus) capable of influence the pathogenesis of age-associated syndromes, as well as to assess the prospects of creating drugs for the prevention of geriatric diseases on the basis of this compound.

MATERIALS AND METHODS

A search query in the PubMed, Scopus, Google Scholar, e-Library databases was performed by the following keywords: «astragaloside IV», «Alzheimer’s disease», «Parkinson’s disease», «atherosclerosis», «osteoporosis», «osteoarthritis», «age-related macular degeneration».

RESULTS

It has been established that astragaloside IV affects the probable mechanisms of onset and development of age-associated syndromes’ complex, such as Alzheimer’s disease, Parkinson’s disease, atherosclerosis, osteoporosis and osteoarthritis, age-related macular degeneration. This saponin affects the specific pathogenetic processes of these diseases at different levels through a spectrum of signaling pathways.

CONCLUSION

Astragaloside IV deserves special attention as a candidate for creation of effective multipurpose means of prevention or slowing of a number of age-associated diseases development. Nevertheless, the process of investigating this compound as a prophylactic agent is far from complete. Clinical trials, establishment of preventive doses, frequency and duration of administration are required. Safety in long-term use should be examined separately.

Keywords:

astragaloside IV

Alzheimer’s disease

Parkinson’s disease

atherosclerosis

osteoporosis

osteoarthritis

age-related macular degeneration

Authors:

Berezutsky M.A.

Saratov State Medical University named after V.I. Razumovsky

ORCID: 0000-0003-0433-8247

Matvienko U.A.

Saratov State Medical University named after V.I. Razumovsky

ORCID: 0000-0002-1714-9165

Durnova N.A.

Saratov State Medical University named after V.I. Razumovsky;
I.M. Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0003-4628-9519

Received:

16.01.2025

Accepted:

06.05.2025

Close metadata

References:

Liang Y, Chen B, Liang D, et al. Pharmacological effects of astragaloside IV: a review. Molecules. 2023;28(16):6118.
Costa IM, Lima FO, Fernandes LC, et al. Astragaloside IV supplementation promotes a neuroprotective effect in experimental models of neurological disorders: a systematic review. Current Neuropharmacology. 2019;17(7):648-665. https://doi.org/10.2174/1570159X16666180911123341
Yang K, Xie Q, Tang T, et al. Astragaloside IV as a novel CXCR4 antagonist alleviates osteoarthritis in the knee of monosodium iodoacetate-induced rats. Phytomedicine. 2023;108:154506. https://doi.org/10.1016/j.phymed.2022.154506
Liu HS, Shi HL, Huang F, et al. Astragaloside IV inhibits microglia activation via glucocorticoid receptor mediated signaling pathway. Scientific Reports. 2016;6(1):19137. https://doi.org/10.1038/srep19137
Breijyeh Z, Karaman R. Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules. 2020;25(24):5789. https://doi.org/10.3390/molecules25245789
Yang Z, Liu B, Yang LE. Platycodigenin as Potential Drug Candidate for Alzheimer’s Disease via Modulating Microglial Polarization and Neurite Regeneration. Molecules. 2019;24(18):3207. https://doi.org/10.3390/molecules24183207
He L, Sun J, Miao Z, et al. Astragaloside IV attenuates neuroinflammation and ameliorates cognitive impairment in Alzheimer’s disease via inhibiting NF-κB signaling pathway. Heliyon. 2023;9(2):13411. https://doi.org/10.1016/j.heliyon.2023.e13411
Chen F, Yang D, Cheng XY, et al. Astragaloside IV ameliorates cognitive impairment and neuroinflammation in an oligomeric Aβ induced Alzheimer’s disease mouse model via inhibition of microglial activation and NADPH oxidase expression. Biological and Pharmaceutical Bulletin. 2021;44(11): 1688-1696. https://doi.org/10.1248/bpb.b21-00381
Chang Y, Bai M, Zhang X, et al. Neuroprotective and acetylcholinesterase inhibitory activities of alkaloids from Solanum lyratum Thunb.: An in vitro and in silico analyses. Phytochemistry. 2023;209:113623. https://doi.org/10.1016/j.phytochem.2023.113623
Stępnik K, Kukula-Koch W. In silico studies on triterpenoid saponins permeation through the blood-brain barrier combined with postmortem research on the brain tissues of mice affected by Astragaloside IV Administration. International Journal of Molecular Sciences. 2020;21(7):2534. https://doi.org/10.3390/ijms21072534
Ghatak S, Dolatabadi N, Trudler D, et al. Mechanisms of hyperexcitability in Alzheimer’s disease hiPSC-derived neurons and cerebral organoids vs isogenic controls. Elife. 2019;8:50333. https://doi.org/10.7554/eLife.50333
Yue R, Li X, Chen B, et al. Astragaloside IV attenuates glutamate-induced neurotoxicity in PC12 cells through Raf-MEK-ERK pathway. PLoS One. 2015;10(5):0126603. https://doi.org/10.1371/journal.pone.0126603
Liu Y, Chong L, Li X, et al. Astragaloside IV rescues MPP+-induced mitochondrial dysfunction through upregulation of methionine sulfoxide reductase A. Experimental and Therapeutic Medicine. 2017;14(3):2650-2656. https://doi.org/10.3892/etm.2017.4834
Misrani A, Tabassum S, Yang L. Mitochondrial dysfunction and oxidative stress in Alzheimer’s disease. Frontiers in Aging Neuroscience. 2021;13:617588. https://doi.org/10.3389/fnagi.2021.617588
Ma Y, Xiong L. Astragaloside IV ameliorates endoplasmic reticulum stress-induced apoptosis of Aβ25-35-treated PC12 cells by inhibiting the p38 MAPK signaling pathway. Molecular Medicine Reports. 2019;19(3):2005-2012. https://doi.org/10.3892/mmr.2019.9855
Wang X, Gao F, Xu W, et al. Depichering the effects of astragaloside IV on AD-like phenotypes: a systematic and experimental investigation. Oxidative Medicine and Cellular Longevity. 2021;2021:1020614. https://doi.org/10.1155/2021/1020614
Wang X, Xu W, Chen H, et al. Astragaloside IV prevents Aβ1-42 oligomers-induced memory impairment and hippocampal cell apoptosis by promoting PPARγ/BDNF signaling pathway. Brain Research. 2020;1747:147041. https://doi.org/10.1016/j.brainres.2020.147041
Yin Y, Yan L, Huang LQ, et al. Anti-apoptosis effect of astragaloside IV on Alzheimer’s disease rat model via enhancing the expression of Bcl-2 and Bcl-xl. Scandinavian Journal of Laboratory Animal Science. 2010;37(2):75-82. https://doi.org/10.23675/sjlas.v37i2.206
Yu C, Zhang J, Li X, et al. Astragaloside IV-induced Nrf2 nuclear translocation ameliorates lead-related cognitive impairments in mice. Biochimica et Biophysica Acta (BBA) — Molecular Cell Research. 2021;1868(1):118853. https://doi.org/10.1016/j.bbamcr.2020.118853
Chan WS, Durairajan SSK, Lu JH, et al. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture. Neurochemistry International. 2009;55(6):414-422. https://doi.org/10.1016/j.neuint.2009.04.012
Liu X, Zhang J, Wang S, et al. Astragaloside IV attenuates the H2O2-induced apoptosis of neuronal cells by inhibiting α-synuclein expression via the p38 MAPK pathway. International Journal of Molecular Medicine. 2017;40(6):1772-1780. https://doi.org/10.3892/ijmm.2017.3157
Xia L, Guo D, Chen B. Neuroprotective effects of astragaloside IV on Parkinson disease models of mice and primary astrocytes. Experimental and Therapeutic Medicine. 2017;14(6):5569-5575. https://doi.org/10.3892/etm.2017.5238
Xia ML, Xie XH, Ding JH, et al. Astragaloside IV inhibits astrocyte senescence: implication in Parkinson’s disease. Journal of Neuroinflammation. 2020;17(10):1-13. https://doi.org/10.1186/s12974-020-01791-8
Björkegren JL, Lusis AJ. Atherosclerosis: recent developments. Cell. 2022; 185(10):1630-1645. https://doi.org/10.1016/j.cell.2022.04.004
Sun D, Wang Y, Pang B, et al. Astragaloside IV Mediates the PI3K/Akt/mTOR Pathway to Alleviate Injury and Modulate the Composition of Intestinal Flora in ApoE-/-Atherosclerosis Model Rats. Discovery Medicine. 2024; 36(184):1070-1079.
Qin HW, Sun MY, Wang MN, et al. [Mechanism of astragaloside IV modulation of Nrf2/HO-1/GPX4 pathway to inhibit ferroptosis and ameliorate atherosclerosis in ApoE~(–/–)mice]. Zhongguo Zhong yao za zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica. 2024;49(13): 3619-3626. https://doi.org/10.19540/j.cnki.cjcmm.20240321.702
Hewei Q, Ping L. GW25-e0074 Effects of Astragaloside IV on the SDF-1/CXCR4 Expression in Atherosclerosis of ApoE(–/–)Mice Induced by Hyperlipaemia. Journal of the American College of Cardiology. 2014;64(16S):28-C28.
Qin HW, Zhang QS, Li YJ, et al. Molecular mechanism of astragaloside — against atherosclerosis by regulating miR-17-5p and PCSK9/VLDLR signal pathway. Zhongguo Zhong yao za zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica. 2022;47(2):492-498. https://doi.org/10.19540/j.cnki.cjcmm.20210918.701
Shao X, Liu Z, Liu S, et al. Astragaloside IV alleviates atherosclerosis through targeting circ_0000231/miR-135a-5p/CLIC4 axis in AS cell model in vitro. Molecular and Cellular Biochemistry. 2021;476:1783-1795. https://doi.org/10.1007/s11010-020-04035-8
Guo LH, Cao Y, Zhuang RT, et al. Astragaloside IV promotes the proliferation and migration of osteoblast-like cells through the hedgehog signaling pathway. International journal of Molecular Medicine. 2019;43(2):830-838. https://doi.org/10.3892/ijmm.2018.4013
Sun NY, Liu XL, Gao J, et al. Astragaloside-IV modulates NGF-induced osteoblast differentiation via the GSK3β/β-catenin signalling pathway. Molecular Medicine Reports. 2021;23(1):1. https://doi.org/10.3892/mmr.2020.11657
Jing WB, Ji H, Jiang R, et al. Astragaloside positively regulated osteogenic differentiation of pre-osteoblast MC3T3-E1 through PI3K/Akt signaling pathway. Journal of Orthopaedic Surgery and Research. 2021;16:1-10. https://doi.org/10.1186/s13018-021-02690-1
Ou L, Kang W, Zhang J, et al. Network pharmacology-based investigation on the anti-osteoporosis mechanism of astragaloside IV. Natural Product Communications. 2021;16(7):1934578X211029549. https://doi.org/10.1177/1934578X211029549
Wang F, Qian H, Kong L, et al. Accelerated bone regeneration by astragaloside IV through stimulating the coupling of osteogenesis and angiogenesis. International Journal of Biological Sciences. 2021;17(7):1821. https://doi.org/10.7150/ijbs.57681
Li M, Wang W, Geng L, et al. Inhibition of RANKL-induced osteoclastogenesis through the suppression of the ERK signaling pathway by astragaloside IV and attenuation of titanium-particle-induced osteolysis. International Journal of Molecular Medicine. 2015;36(5):1335-1344. https://doi.org/10.3892/ijmm.2015.2330
Liu J, Meng Q, Jing H, et al. Astragaloside IV protects against apoptosis in human degenerative chondrocytes through autophagy activation. Molecular Medicine Reports. 2017;16(3):3269-3275. https://doi.org/10.3892/mmr.2017.6980
Xu H, Jing-Bo W, Chen YP, et al. Astragaloside IV protects against IL-1β-induced chondrocyte damage via activating autophagy. Current Molecular Medicine. 2024;24(11):1382-1389. https://doi.org/10.2174/0115665240249154231016080115
Li M, Xu J, Wang Y, et al. Astragaloside A Protects Against Photoreceptor Degeneration in Part Through Suppressing Oxidative Stress and DNA Damage-Induced Necroptosis and Inflammation in the Retina. Journal of Inflammation Research. 2022;15:2995-3020. https://doi.org/10.2147/JIR.S362401
Kozlowski MR, Bond KE, Manesh MN. Inhibition of senescence in RPE cells by astragaloside IV: implications for treating AMD. Investigative Ophthalmology and Visual Science. 2015;56(7):178-178.
Chen BY, Liou JC, Wu JL, et al. Photoreceptor and vision protective effects of astragaloside IV in mice model with light-evoked retinal damage. Biomedicine and Pharmacotherapy. 2022;153:113404. https://doi.org/10.1016/j.biopha.2022.113404
Song Q, Zhao Y, Yang Y, et al. Astragaloside IV protects against retinal iron overload toxicity through iron regulation and the inhibition of MAPKs and NF-κB activation. Toxicology and Applied Pharmacology. 2021;410:115361. https://doi.org/10.1016/j.taap.2020.115361
Chen PJ, Shang AQ, Wang WW, et al. Astragaloside suppresses tumor necrosis factor receptor-associated factor 5 signaling pathway and alleviates neurodegenerative changes in retinal pigment epithelial cells induced by isoflurane. Journal of Cellular Biochemistry. 2019;120(1):1028-1037. https://doi.org/10.1002/jcb.27599